Skip to content
Screener

Alumis Inc. ALMS EBITDA margin

EBITDA margin at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
30.7%+3.6pp
Amgen logo
AmgenAMGN
42.2%+3.0pp
Immunome logo
ImmunomeIMNM
-5,886.7%-11,897pp
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-15,497.7%-17,225pp
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
24.1%+12.9pp
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
-1,045%+263pp

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.51B+691%
Enterprise value$3.48B+953%
P/S417.7×—

Profitability

See full
Operating margin-5,364%—
Net margin-2,825.7%—
FCF margin-4,487.4%—

Returns & leverage

See full
Return on equity-64.6%—
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Calculated from Alumis Inc.’s reported figures.

ebitda/total revenue=-5,322.1%

Based on trailing twelve months.

The source filing: Alumis Inc.’s 10-Q, filed May 14, 2026. Open the filing →

Filed
May 14, 2026, 4:16 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001847367-26-000010

FAQ

What is Alumis Inc.'s EBITDA margin?
Alumis Inc. (ALMS) reported EBITDA margin of -5,322.1% in Q1 2026.
What does EBITDA margin mean?
EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.

Ask your AI about Alumis Inc.'s ebitda margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude